ClinicalTrials.gg
CompletedNCT00646386Updated Mar 28, 2008

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

A Phase 2 interventional study of adalimumab and placebo for adalimumab in Arthritis and Psoriatic, sponsored by Abbott. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-03-28.

Sponsored by Abbott · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies testing adalimumab in Arthritis — none open to participants now, 1 under way, 1 of them phase 3. Adalimumab · Arthritis.

Enrollment
8th of 17
315 · median 149
Started
2003
with 1 other
Phase 2
2 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
2 of 17
Abbott

Among the 17 studies testing adalimumab in Arthritis, this one is the 8th largest by enrollment, is one of 2 that started in 2003, is one of 2 in phase 2, and was the 2nd registered.

Arthritis

843 studies on the registry are indexed under Arthritis; 118 are open to participants now.

Browse Arthritis studies →

Open to participants now

None of the 17 studies testing adalimumab in Arthritis is open now. The open studies under Arthritis, anywhere →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing adalimumab in Arthritis as a file.
02

Study summary

Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis

03

Conditions studied

  • Arthritis
  • Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe PsA
  • Inadequate response to DMARD therapy
  • stable dose \<= 10 mg QD
  • DMARDs must have been taken for 3 months and stable dose for 4 weeks
  • MTX maximum dose = \<= 30 mg/week
  • Active chronic plaque PS or documented history of chronic plaque PS

Exclusion criteria

Exclusion Criteria:

  • No other active skin disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
315 participants (actual)

Study arms

  • Active comparator
    A

    Drug: adalimumab

  • Placebo comparator
    B

    Drug: placebo for adalimumab

Interventions

  • 40 mg eow Week 0 - Week 24

    Also known as: ABT-D2E7, Humira

  • Drugplacebo for adalimumab

    40 mg eow Week 0 - Week 24

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. ACR20

    Time frame: Week 12

  2. Adverse Events

    Time frame: Throughout study participation

  3. Sharp Score

    Time frame: Week 24

Secondary outcomes

  1. ACR20, 50, 70

    Time frame: Weeks 12, 24

  2. Modified Psoriatic Arthritis Response Criteria, HAQ, SF-36, Physician's Global Assessment, PASI, DLQI

    Time frame: Weeks 12 and 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Landewe R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC. Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. Rheumatology (Oxford). 2019 Jun 1;58(6):1025-1033. doi: 10.1093/rheumatology/key417. PubMed 30608620 ↗
  • Mease PJ, Heckaman M, Kary S, Kupper H. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol. 2013 May;40(5):647-52. doi: 10.3899/jrheum.120970. Epub 2013 Mar 15. PubMed 23504383 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a primary completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2008
First posted
Mar 28, 2008
Start
Mar 2003
Primary completionActual
Apr 2004
Last update
Mar 28, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00646386
Lead sponsor
Abbott
First posted
Mar 28, 2008
Start date
Mar 2003
Primary completion
Apr 2004
Last update
Mar 28, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion